Pharmaceuticals

The COVID-19 pandemic has put the spotlight on the FDA drug approval process. Why will it take so long for a vaccine to get approved?

Vaccines and therapies can’t come soon enough for a world facing an unprecedented threat from COVID-19.

All eyes are on those on the front lines seeking to develop and produce new drugs. There’s unprecedented pressure to offer both immediate treatments for those affected and long-term biotherapies and vaccines to prevent future epidemics.

The COVID-19 pandemic will have far-reaching implications, including supply chain disruptions for pharmaceutical manufacturers.

Instruments in today’s market are heavily data-driven and connected. Live information about your process can be accessed at the field level without having to be networked through a traditional HMI (human-machine interface). Learn how Industry 4.0 incorporates the data and analytics from smart instruments to add tremendous value to an organization.

There are many benefits to adding highly potent drug products to your portfolio, including increasing demand and generating potentially higher profit margins. Making the decision to incorporate highly potent drug products into your manufacturing facility can be a challenging process.